Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalbuphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 10/20 | 1.00 |
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalbuphine SCHEMBL3118641 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL3118636 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL12945211 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL10103725 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL13225650 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL19199045 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL16310791 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL17168336 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL21090866 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL4545390 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0024690-B1 | ANALGESIC MIXTURE OF NALBUPHINE AND ACETYLSALICYLIC ACID, DERIVATIVE OR SALT THEREOF | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-07-20 | — | — | EP | claimed |
| JP-6024988-A | — | — | None | — | — | JP | disclosed |
| US-20210330667-A1 | TOPICAL COMPOSITION OF NALBUPHINE AND METHOD FOR TREATING PRURITUS CONDITION, PAIN, OR INFLAMMATORY CONDITION BY USING THE SAME | LUMOSA THERAPEUTICS CO., LTD. (TW) | 2021-10-28 | — | — | US | disclosed |
| WO-2017046814-A1 | A SAFE AND ENVIRONMENT FRIENDLY PROCESS FOR PRODUCING NALBUPHINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RUSAN PHARMA LIMITED (IN) | 2017-03-23 | — | — | WO | disclosed |
| US-20150359789-A1 | METHODS FOR TREATING PRURITUS | Trevi Therapeutics, Inc. | 2015-12-17 | — | — | US | disclosed |
| US-20090060871-A1 | ADMINISTRATION OF AGONIST-ANTAGONIST IN OPIOID-DEPENDENT PATIENTS | VORONKOV MICHAEL VICTOR | 2009-03-05 | — | — | US | disclosed |
| JP-H0624988-A | ANALGESIC AND NARCOTIC-ANTAGONISTIC DRUG FOR ORAL ADMINISTRATION | DU PONT MERCK PHARMACEUT CO | 1994-02-01 | — | — | JP | disclosed |
| US-4990617-A | Analgesics, narcotic antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-02-05 | — | — | US | disclosed |
| EP-0170090-B1 | SUBSTITUTED BENZOATE ESTER PRODRUG DERIVATIVES OF 3-HYDROXYMORPHINANS, INTERMEDIATES THERETO, AND PROCESSES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4722928-A | N-OXIDES OF NALBUPHINE, NALTREXONE AND NALOXONE; ANALGESICS, APPETITE DEPRESSANTS, NARCOTIC ANTAGONIST | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-02 | — | — | US | disclosed |
| US-4407804-A | SYNERGISTIC | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| US-4404209-A | SYNERGISM | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4404210-A | SYNERGISM | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4404208-A | SYNERGISM | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4404211-A | SYNERGISM | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4402962-A | Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-09-06 | — | — | US | disclosed |
| EP-0019282-B1 | ANALGESIC MIXTURE OF NALBUPHINE AND ACETAMINOPHEN | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
| US-4282215-A | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| EP-0024690-A1 | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-11 | — | — | EP | disclosed |
| EP-0019282-A1 | Analgesic mixture of nalbuphine and acetaminophen | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060871-A1 | ADMINISTRATION OF AGONIST-ANTAGONIST IN OPIOID-DEPENDENT PATIENTS | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRD1 5/4885 |
| US-20150359789-A1 | METHODS FOR TREATING PRURITUS | ITCH, HRH2, HRH4 | OPRM1 647/4885OPRK1 213/4885OPRD1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.